BiomX Inc.

BiomX Inc. announced that NYSE Regulation accepted its plan to regain compliance with the exchange's continued listing standards. The company has been granted a plan period until September 25, 2027, to address its non-compliance, which stemmed from a stockholders' deficit of $(1,302,000) as of December 31, 2025, and sustained losses. While its common stock will continue to trade on NYSE American with a ".BC" indicator, the company acknowledges there are no assurances it will successfully regain compliance within the specified timeframe.

BiomX Inc. announced that NYSE Regulation accepted its plan to regain compliance with NYSE American listing standards, granting a plan period through September 25, 2027. The company had previously received a notice of non-compliance on March 25, 2026, due to a stockholders’ deficit of $(1.302 million) as of December 31, 2025, and sustained losses. During this period, BiomX's common stock will continue to be listed and traded on the NYSE American, and the company intends to implement its plan to meet the listing requirements.

BiomX Inc. announced the publication of a new review by Idan Wasserman, CEO of its subsidiary Zorronet Ltd., titled "The Security Industry Has Mistaken Seeing More With Being Safer." The review argues that the next phase of AI-enabled security requires systems that can transform information into true understanding and coordinated action, emphasizing the importance of cultural, local, and situational context. BiomX CEO Michael Oster noted that this aligns with the company's focus on technologies supporting awareness, decision-making, and response. Zorronet is developing an Autonomous Command Center designed to unify security systems and use AI for detection, classification, prioritization, and response coordination across various applications.

BiomX Inc. has filed its Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders, scheduled to be held virtually on June 26, 2026. Key proposals include the election of Ran Shaked as a director, an amendment to the 2026 Equity Incentive Plan to increase the share reserve by 5,460,000 to 6,850,000, and an adjournment proposal. The company also disclosed auditor fees for fiscal years 2025 and 2024, with total fees amounting to $283,000 and $226,393, respectively.

BiomX Inc. issued 1,013,637 restricted shares of common stock to three assignees on June 2, 2026. This issuance resulted from the partial conversion of an outstanding convertible promissory note, originally issued to Mandragola Ltd., involving approximately $379,000 in principal. The note is part of a previously disclosed $2,000,000 revolving Line of Credit Agreement with Mandragola Ltd. Additionally, BiomX issued a five-year warrant to Mandragola to purchase up to 2,000,000 shares at an exercise price of $12.00 per share, contingent on stockholder approval. Following this transaction, the company has 11,160,153 shares of common stock issued and outstanding.

BiomX Inc. announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to support the company's expansion into the defense, security, critical infrastructure, and first-response sectors. Prof. Sarusi brings extensive experience from academia, the defense industry, and commercial ventures, including senior leadership roles at Elbit Systems Electro-Optics and board positions at various defense and technology companies. His expertise is expected to significantly advance BiomX's ability to evaluate new opportunities and align its growth strategy with the operational realities of these critical markets.

BiomX Inc. announced that its Zorronet subsidiary has expanded its autonomous C5ISR suite to support fully secure on-premise, hybrid, and closed-loop deployments. This expansion allows organizations in defense, security, and critical infrastructure to run the full suite locally without relying on the public cloud, addressing regulatory and cybersecurity requirements. The C5ISR market is projected to reach $189 billion by 2030, driven by demand for secure, real-time situational awareness and faster command decision-making.

BiomX Inc. announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), bolstering its senior business and operational leadership. This strategic hire supports the company's focus on defense, security, and first response technologies, particularly in UAS and autonomous counter-UAS capabilities. Mr. Timor-Rousso brings extensive military leadership experience from the Israel Defense Forces and over two decades in technology, including roles at 11Stream, Flexnode, and Pente Networks, where he helped drive significant growth and investment. His appointment is key to BiomX's transition from strategy to execution in the defense technology sector.

BiomX Inc. reported a net loss of $19,140K for the first quarter of 2026, a significant increase from $7,659K in the same period last year, and an accumulated deficit of $236,036K as of March 31, 2026. The company issued a going concern warning, stating that current funds and expected revenues will only be sufficient for the next several months. This financial update follows a strategic transition to defense, security, and critical infrastructure technology markets, including the deconsolidation of its former biopharmaceutical subsidiary, BiomX Israel, due to insolvency proceedings.

BiomX Inc. announced that its Zorronet subsidiary has launched a secure, AI-powered mobile application, now available on Google Play and the Apple App Store. The app integrates various surveillance and IoT devices into a unified system, providing field operators with structured alerts and real-time operational views. This innovation aims to enhance security, streamline coordination, and reduce manual effort, addressing a global command and control systems market projected to reach approximately $44 billion by 2030.